Ryan Zimmerman is ranked #2431 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Ryan Zimmerman (BTIG) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Ryan Zimmerman's stock ratings?

About 44% of Ryan's ratings were profitable over a one-year hold, with an average return of -2.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Ryan Zimmerman

BTIG

Ryan Zimmerman

BTIG

Wall Street Analyst

★☆☆☆☆

#2431

on 13Foresight · ranked by our own returns

43%

Success Rate

-2.5%

Average Return

26 of 61 calls profitable · -9.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 43% of Ryan Zimmerman's ratings turned a profit when each position was held for 1 year — averaging -2.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

151 Buy 74 Hold 3 Sell

Ryan's Stock Coverage 38 ratings · 2026-07-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
SOLV Solventum Corporation	Jul 13, 2026	BUY	Buy +11.9% avg upside 15 analysts	$91.00 17.52% Upside	-1.5%
GEHC GE Healthcare Technologies Inc	Jul 13, 2026	BUY	Buy +30.5% avg upside 22 analysts	$75.00 14.86% Upside	-3.0%
GKOS Glaukos	Jul 13, 2026	BUY	Strong Buy -7.8% avg upside 21 analysts	$164.00 7.32% Upside	-0.2%
SYK Stryker	Jul 13, 2026	BUY	Strong Buy +19.3% avg upside 37 analysts	$371.00 11.91% Upside	-6.2%
MDT Medtronic	Jul 13, 2026	BUY	Buy +19.9% avg upside 38 analysts	$91.00 8.91% Upside	-5.1%
ISRG Intuitive Surgical	Jul 13, 2026	BUY	Strong Buy +36.0% avg upside 36 analysts	$512.00 25.82% Upside	-3.9%
ENOV Enovis	Jul 06, 2026	BUY	Buy +172.8% avg upside 37 analysts	$39.00 48.51% Upside	-0.0%
ZBH Zimmer Biomet Holdings	Jun 30, 2026	HOLD	Buy +21.7% avg upside 38 analysts	—	+6.5%
GMED Globus Medical	Jun 22, 2026	HOLD	Strong Buy +22.6% avg upside 24 analysts	—	-1.5%
IART Integra Lifesciences	Jun 22, 2026	HOLD	Buy +129.2% avg upside 21 analysts	—	+0.5%
MOBI Mobia Medical, Inc.	Jun 22, 2026	BUY	Strong Buy +77.0% avg upside 4 analysts	$19.00 66.75% Upside	·
CARL Carlsmed, Inc.	Jun 22, 2026	BUY	Strong Buy +65.8% avg upside 6 analysts	$23.00 90.01% Upside	·
HUMA Humacyte	Jun 22, 2026	BUY	Strong Buy +844.3% avg upside 11 analysts	$2.00 189.26% Upside	-15.5%
LNSR LENSAR	Jun 22, 2026	BUY	Strong Buy +111.2% avg upside 4 analysts	$7.00 20.23% Upside	·
KIDS OrthoPediatrics	Jun 22, 2026	BUY	Strong Buy +52.7% avg upside 10 analysts	$24.00 15.92% Upside	·
ORGO Organogenesis Holdings	Jun 22, 2026	HOLD	Strong Buy +398.3% avg upside 8 analysts	—	+1.2%
RCEL Avita Medical	Jun 22, 2026	HOLD	Strong Buy +177.4% avg upside 10 analysts	—	·
PRCT PROCEPT BioRobotics	Jun 02, 2026	HOLD	Buy +87.8% avg upside 17 analysts	—	-28.1%
MDAI Spectral AI	May 26, 2026	BUY	Strong Buy +168.3% avg upside 3 analysts	$4.00 138.16% Upside	-20.2%
TCMD Tactile Systems Technology	May 21, 2026	BUY	Strong Buy +46.1% avg upside 8 analysts	$40.00 37.72% Upside	+7.8%
STAA Staar Surgical	May 14, 2026	HOLD	Hold +21.1% avg upside 16 analysts	—	-12.1%
SI Shoulder Innovations, Inc.	May 13, 2026	BUY	Strong Buy -4.2% avg upside 5 analysts	$24.00 7.31% Upside	+57.2%
RXST RxSight	May 07, 2026	HOLD	Buy +98.7% avg upside 13 analysts	—	+3.5%
VCEL Vericel	Apr 05, 2026	HOLD	Strong Buy -0.9% avg upside 16 analysts	—	+37.9%
XTNT Xtant Medical Holdings	Mar 31, 2026	BUY	Strong Buy +1432.0% avg upside 9 analysts	$1.00 145.08% Upside	-17.9%
CH:ALC Alcon	Mar 23, 2026	BUY	Buy +30.6% avg upside 35 analysts	$74.53 33.30% Upside	·
PEN Penumbra	Feb 18, 2026	HOLD	Buy +4.2% avg upside 23 analysts	—	-6.8%
RBOT Vicarious Surgical	Nov 13, 2025	HOLD	Buy +7357.7% avg upside 6 analysts	—	-95.5%
TMCI Treace Medical Concepts	Nov 07, 2025	HOLD	Hold +18.4% avg upside 8 analysts	—	+4.4%
OFIX Orthofix Medical	Feb 25, 2025	HOLD	Buy +156.2% avg upside 15 analysts	—	-25.5%
IRTC Irhythm Technologies	Oct 16, 2023	BUY	Strong Buy +45.6% avg upside 19 analysts	$132.00 11.20% Upside	-26.8%
AXGN AxoGen	Aug 18, 2023	HOLD	Strong Buy -13.6% avg upside 21 analysts	—	+104.0%
PODD Insulet	Apr 17, 2023	BUY	Strong Buy +61.5% avg upside 32 analysts	$350.00 115.97% Upside	-48.2%
GE GE Aerospace	Apr 10, 2023	HOLD	Strong Buy -32.6% avg upside 49 analysts	—	+108.4%
MDWD Mediwound	Oct 14, 2022	HOLD	Strong Buy +51.2% avg upside 13 analysts	—	-3.7%
ECOR Electrocore	Jul 30, 2021	HOLD	Buy +594.4% avg upside 10 analysts	—	-44.6%
ABT Abbott Laboratories	Aug 27, 2020	HOLD	Strong Buy +29.6% avg upside 36 analysts	—	+13.6%
OCGN Ocugen	Dec 24, 2018	HOLD	Strong Buy +549.6% avg upside 17 analysts	—	-95.0%

🔒 33 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Ryan Zimmerman — Frequently Asked Questions

How accurate are Ryan Zimmerman's stock ratings?

Based on the calls 13Foresight could measure, about 44% of Ryan's ratings were profitable over a one-year hold, with an average return of -2.6% per rating, or -10.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Ryan ranked on 13Foresight?

Ryan Zimmerman is currently ranked #2431 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Ryan cover?

Ryan most recently has ratings on SOLV, GEHC, GKOS, SYK, MDT, ISRG, ENOV, ZBH, GMED, IART, MOBI, CARL and 26 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!